Menu
Search
|

Menu

Close
X

Exact Sciences Corp EXAS.OQ (NASDAQ Stock Exchange Capital Market)

42.37 USD
-2.62 (-5.82%)
As of 2:29 AM IST
chart
Previous Close 44.99
Open 40.90
Volume 3,026,824
3m Avg Volume 707,014
Today’s High 42.65
Today’s Low 38.90
52 Week High 63.60
52 Week Low 19.93
Shares Outstanding (mil) 119.10
Market Capitalization (mil) 5,791.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY17
266
FY16
99
FY15
39
EPS (USD)
FY17
-2.037
FY16
-1.646
FY15
-1.713
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
34.20
5.77
Price to Book (MRQ)
vs sector
10.71
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.94
16.52
LT Debt to Equity (MRQ)
vs sector
0.91
12.22
Return on Investment (TTM)
vs sector
-34.68
14.43
Return on Equity (TTM)
vs sector
-35.62
16.13

EXECUTIVE LEADERSHIP

Kevin Conroy
Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $575,000.00
Bonus: $625,313.00
Jeffrey Elliott
Chief Financial Officer, Since 2016
Salary: $157,835.00
Bonus: $108,156.00
Maneesh Arora
Chief Operating Officer, Senior Vice President, Director, Since 2013
Salary: $453,200.00
Bonus: $394,284.00
Graham Lidgard
Senior Vice President, Chief Scientific Officer, Since 2009
Salary: $391,400.00
Bonus: $227,012.00
D. Scott Coward
Senior Vice President, General Counsel, Secretary, Since 2015
Salary: $370,800.00
Bonus: $241,947.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

441 Charmany Dr
MADISON   WI   53719-1234

Phone: +1608.2845700

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

SPONSORED STORIES